Supplemental figure 2.pdf (85.13 kB)
Supplemental Figure 2. Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines
figure
posted on 2021-05-14, 09:24 authored by Alessandro Dal Maso, Martina Lorenzi, Alessandra Ferro, Sara Pilotto, Fabiana Cecere, Alessandro Follador, Valentina Polo, Alessandro Del Conte, Giulia Sartori, Marco Giavarra, Daniela Scattolin, Stefano Indraccolo, Stefano Frega, Giovanna De Maglio, Jessica Menis, Laura Bonanno, Fiorella Calabrese, Valentina Guarneri, PierFranco Conte, Giulia Pasello|
Supplementary Figure 2.
Real world data on treatment outcomes in EGFR mutant NSCLC patients receiving
osimertinib in second or further lines
Univariate odds ratios for progression pattern. An odds ratio > 1 shows an association with EGFR T790M mutation, whereas an odds ratio < 1 with EGFR T790M mutation negativity. 95% confidence intervals for odds ratios are plotted. PD, progression.
|
